Osteosarcoma Maintenance Therapy With OST31-164 (OST-164-01)

  • End date
    Aug 13, 2023
  • participants needed
  • sponsor
    George Clinical Pty Ltd
Updated on 13 June 2022


Up to 45 Patients aged 12 to 39 with osteosarcoma (bone cancer) that had recurred in the lungs and has recently been surgically removed will be enrolled. Patients will receive OST31-164 infusions every 3 weeks over 48 weeks and be followed after that for 3 years.


This is a Phase 2, open-label, multicenter, single-arm study in patients (12-39 years) with a recent history of pulmonary recurrent osteosarcoma that has been completely resected. Planned enrollment is a maximum of 45 patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria. Following treatment discontinuation, all patients will enter a 3-year survival follow-up period. Exploratory evaluation of immune response will be conducted. If available, tissue from the recent resection will be sent to the COG Biobank for future genomic and pathologic analysis by the COG.

Condition Bone Cancer
Treatment OST31-164
Clinical Study IdentifierNCT04974008
SponsorGeorge Clinical Pty Ltd
Last Modified on13 June 2022


Yes No Not Sure

Inclusion Criteria

Note: Patients enrolled on AOST2031 are eligible for enrollment in the present study
Patients are eligible to be included in the study only if all the following
criteria apply
Age and Weight
Between 12 years of age and 39 years of age at the time the Informed Consent/ Assent form is signed
Weight at least 40 kg. Diagnosis
Has histologic confirmation of osteosarcoma at diagnosis
Has at least one episode of disease recurrence in the lungs without limitation on the number of episodes of recurrence as long as the following criteria are met
Surgical resection of all possible sites of suspected pulmonary metastases to achieve a complete remission within 8 weeks prior to study enrollment
Pathological confirmation of osteosarcoma from at least one resected tumor
Patients will not require radiographic confirmation of complete remission for enrollment. However, a postoperative CT chest scan is required as a baseline for future comparisons
ook.pdf) Performance Status
Patient must have a performance status corresponding to ECOG scores of 0, 1, or 2. Use
Karnofsky scale for patients > 16 years of age and Lansky scale for patients < years
of age Prior Therapy
Patient must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, radiotherapy, or surgery prior to entering this study
Organ Function Requirements
Patient has adequate organ function as defined below
a. Hematological: i. Absolute neutrophil count (ANC) is at least 1,000/µL without
transfusion or growth factor support. ii. Platelet count ≥ 50,000/µL without
Maximum Serum Creatinine (mg/dL)
transfusion or growth factor support. b. Adequate renal function defined as: i
Creatine clearance or radioisotope glomerular filtration rate (GFR) > 70 mL/min/1.73
m2 or ii. A serum creatine based on age/gender as follows
Age: 12 to < 13 years Male :1.2 Female:1.2 Age:13 to < 16 years Male :1.5 Female:1.4
Age: ≥ 16 years Male :1.7 Female:1.4 Note: the threshold for creatinine values in this
table were derived from the Schwartz formula for estimating GFR
c. Adequate liver function defined as: i. Total bilirubin < 1.5 x upper limit of
normal (ULN) for age ii. Serum glutamic-pyruvic transaminase (SGPT) / alanine
aminotransferase (ALT) < 110 U/L (for the purpose of this study the ULN for SGPT is 45
U/L) iii. Serum albumin > 2 g/dL
d. Adequate coagulation i. International normalized ratio (INR) or prothrombin time
(PT) < 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or
ii. Activated partial thromboplastin time (aPTT) < 1.5 x ULN unless patient is
INR is within therapeutic range of intended use of anticoagulants
receiving anticoagulant therapy as long as aPTT is within therapeutic range of
intended use of anticoagulants
e. Adequate cardiac function defined as: i. Shortening fraction of > 27% by
echocardiogram, or ii. Ejection fraction of > 50% by radionuclide angiogram or
echocardiogram f. Adequate pulmonary function defined as: i. No evidence of dyspnea at
rest, no history of exercise intolerance, and a pulse oximetry of > 94%
g. Central nervous system (CNS) function defined as: i. Patients with a known seizure
disorder may be enrolled if on anticonvulsants and/or are well-controlled
ii. CNS toxicity including peripheral neuropathy < Grade 2
Patient and/or patient's parent or legal guardian must be capable of understanding the
investigational nature, potential risks, and benefits of the study. The patient and/or
the parent or legal guardian must sign a written informed consent. Age-appropriate
assent will be obtained per institutional guidelines
A female patient is eligible to participate if she is not pregnant, not breastfeeding
Female patients
and at least one of the following conditions applies
A WOCBP who agrees to follow the contraceptive guidance in the protocol during
Not a woman of childbearing potential (WOCBP) as defined in the protocol OR
the treatment period and for at least 120 days after the last dose of study
A female patient of childbearing potential must have a negative urine or serum
Male patients
pregnancy test within 72 hours prior to receiving any dose of study treatment. If the
urine test is positive or cannot be confirmed as negative, a serum pregnancy test will
be required
A male patient is eligible to participate if he agrees to follow the contraceptive
guidance in the protocol during the study treatment period and for at least 120 days
after the last dose of study treatment

Exclusion Criteria

Has clinically evident metastatic or recurrent disease
Has concurrent pulmonary recurrence and local recurrence at the primary tumor site
Has primary refractory disease with progression of the primary tumor on
Has CNS or any extrapulmonary disease involvement at the time of the most recent
episode of disease recurrence proceeding enrollment
Has active infection requiring systemic therapy or is dependent on or is currently
receiving systemic antibiotics that cannot be discontinued before dosing. (Note
Has a known allergy to any component of the study treatment(s) formulations
Patients who discontinue an antibiotic prior to dosing must wait at least 5 half-lives
after the last dose of antibiotic before receiving any OST31-164 infusion). Inhaled
Has contraindication to administration of NSAIDs
prophylactic PJP (pneumocystis jiroveci pneumonia) treatment is acceptable per
Investigator discretion
Has had a prior monoclonal antibody therapy within 2 weeks prior to study Day 1
Is currently dependent on or has received corticosteroids within the past 4 weeks
(topical corticosteroids and occasional inhaled corticosteroids are allowed)
Has previous history of listeriosis
Is currently participating in or has participated in a study of an investigational
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
agent or is using an investigational device within 4 weeks of the first dose of
Has received a live vaccine within 30 days prior to Study Day 1
Has a history of other active malignancy for < 2 years prior to enrollment. Basal cell
carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer
Regulatory Requirements
that has undergone potentially curative therapy or is felt by the Investigator to be
at low risk for recurrence is allowed
All institutional, FDA, and NCI requirements for human studies must be met
Has an active autoimmune disease requiring systemic treatment within the past 3 months
or a documented history of clinically severe autoimmune disease, or a syndrome that
requires systemic steroids or immunosuppressive agents. Replacement therapy (e.g
thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or
pituitary insufficiency) is not considered a form of systemic treatment. Patients with
vitiligo or resolved childhood asthma/atopy would be an exception to this rule
Patients who require intermittent use of bronchodilators or local steroid injections
will not be excluded from the study. Patients with hypothyroidism stable on hormone
replacement or Sjogren's syndrome will not be excluded from the study
Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial
Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the trial, starting with the pre-screening or screening visit
through 120 days after the last dose of study treatment
Has a contraindication (e.g., sensitivity/allergy) to both trimethoprim
sulfamethoxazole and amoxicillin
Is currently receiving or will be receiving any chemotherapy, including PI3K
inhibitors, during the treatment phase
Requires or anticipates requiring tumor necrosis factor (TNF) blocking agent (e.g
infliximab) therapy for diagnosis of rheumatologic disease or inflammatory bowel
disease (e.g., ankylosing spondylitis, Crohn's disease, plaque psoriasis, psoriatic
arthritis, rheumatoid arthritis, or ulcerative colitis)
Has known active hepatitis B (e.g., HBsAg reactive) or hepatitis C (e.g., HCV RNA
[qualitative] is detected)
Patient is or has an immediate family member (spouse, children, or parent) who is
directly involved with this study or is employed by the investigational site or
Sponsor, unless prospective Institutional Review Board (IRB) approval (by chair or
designee) is given allowing exception to this criterion for a specific patient
All patients and/or their parents or legal guardians must sign a written informed
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note